Recent Finacing
Recent Raise
ABM Therapeutics is a clinical-stage small-molecule R&D platform developing blood–brain-barrier-penetrant compounds targeting MAPK-pathway targets, with lead BRAF brain-penetrant candidate ABM-1310 in multicenter phase I and multiple preclinical programs.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
